A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania
被引:14
|
作者:
Perrin, E.
论文数: 0引用数: 0
h-index: 0
机构:Lilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
Perrin, E.
Anand, E.
论文数: 0引用数: 0
h-index: 0
机构:
Lilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, EnglandLilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
Anand, E.
[1
]
Dyachkova, Y.
论文数: 0引用数: 0
h-index: 0
机构:Lilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
Dyachkova, Y.
Wagner, T.
论文数: 0引用数: 0
h-index: 0
机构:
Lilly Deutschland GmbH, D-61350 Bad Homburg, GermanyLilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
Wagner, T.
[2
]
Frediani, S.
论文数: 0引用数: 0
h-index: 0
机构:
Psychiat Dept Venice, Natl Mental Hlth Serv, Venice, ItalyLilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
Frediani, S.
[3
]
Ballerini, A.
论文数: 0引用数: 0
h-index: 0
机构:
Santa Maria Nuova Hosp, Serv Psichiatr Diagnosi & Cura, Florence, ItalyLilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
Ballerini, A.
[4
]
机构:
[1] Lilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
[2] Lilly Deutschland GmbH, D-61350 Bad Homburg, Germany
This naturalistic, observational pan-European study assessed the safety and early effectiveness of intramuscular (IM) psychotropic treatments in patients with acute agitation suffering from schizophrenia or bipolar mania. One thousand nine hundred and forty of 1945 patients completed the 24-hour observation period after initial IM treatment. Patients from 12 European countries were included (mean age 39 years; 58% male, 66% schizophrenia). IM treatment was at the physician's discretion. The primary objective was to describe the acute tolerability of IM psychotropic therapies in clinical practice, with particular emphasis on EPS. At baseline, 68% of the patients received IM monotherapy, with IM olanzapine most commonly prescribed (36%). During the first 24 hours, 190 (9.8%) patients experienced EPS. The occurrence of EPS was statistically significantly lower in patients treated with IM olanzapine compared to those treated with other IM psychotropic medications (mainly typical antipsychotics and benzodiazepines): acute dystonia: 1.1%, 95% CI 0.5-2.3 and 2.9%, CI 2.0-4.0; akathisia: 2.3%, CI 1.3-3.7 and 5.5%, CI 4.3-6.9; Parkinsonism: 2.9%, CI 1.8-4.4 and 7.8%, CI 6.4-9.4, respectively. Anticholinergic treatment was given to 12% IM olanzapine versus 31% non-olanzapine treated patients. Acute agitation after 24 hours was reduced by 1.68 (95% CI 1.46-1.91) points on the Clinical Global Impression of Severity (CGI-S) in IM olanzapine patients and 1.51 (95% CI 1.30-1.73) points in non-olanzapine patients. Additional psychotropic medication was required for 90% of the patients during the first 24 hours of treatment. Results provide naturalistic evidence for low EPS rates and improvement of agitation with IM psychotropic medications during acute states of patients suffering from acute mania or schizophrenia. (C) 2010 Elsevier Masson SAS. All rights reserved.
机构:Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
Meehan, KM
Wang, HE
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
Wang, HE
David, SR
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
David, SR
Nisivoccia, JR
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
Nisivoccia, JR
Jones, B
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
Jones, B
Beasley, CM
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
Beasley, CM
Feldman, PD
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
Feldman, PD
Mintzer, JE
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
Mintzer, JE
Beckett, LM
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
Beckett, LM
Breier, A
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA